Revival of old antibiotics: pharmacokinetic study of multiple-dose intravenous polymyxin B in patients with severe burn injury undergoing continuous renal replacement therapy

2016 ◽  
Author(s):  
Linlin Hu
Keyword(s):  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Pharmacokinetic Study ◽  
Multiple Dose ◽  
Burn Injury ◽  
Polymyxin B ◽  
Severe Burn ◽  
Severe Burn Injury

scholarly journals Acute Dapsone Overdose: The Effects of Continuous Veno-Venous Haemofiltration on the Elimination of Dapsone

2011 ◽  
Vol 39 (6) ◽  
pp. 1131-1135 ◽  
Author(s):  
V. A. Masurkar ◽  
M. D. Edstein ◽  
C. J. Gorton ◽  
C. M. Anstey
Keyword(s):  
Methylene Blue ◽  
Ascorbic Acid ◽  
Renal Replacement Therapy ◽  
Lactic Acidosis ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Activated Charcoal ◽  
Multiple Dose ◽  
Good Outcome ◽  
Intentional Ingestion

A 15-year-old girl presented after intentional ingestion of dapsone (7.2 g) and small quantities of azathioprine, methotrexate and prednisolone. The resulting methaemoglobinaemia and lactic acidosis persisted despite treatment with methylene blue, multiple-dose activated charcoal and ascorbic acid. Continuous veno-venous haemofiltration for 75 hours was used to treat the dapsone overdose. The patient's serum dapsone concentrations were measured during and after continuous veno-venous haemofiltration. The rate of elimination of dapsone was over three times higher during, compared to after, continuous veno-venous haemofiltration. Continuous renal replacement therapy successfully reduced toxic dapsone concentrations in this patient with a good outcome.

Potential Survival Benefit of Polymyxin B Hemoperfusion in Septic Shock Patients on Continuous Renal Replacement Therapy: A Propensity-Matched Analysis

2016 ◽  
Vol 42 (1) ◽  
pp. 9-17 ◽  
Author(s):  
Masao Iwagami ◽  
Hideo Yasunaga ◽  
Eisei Noiri ◽  
Hiromasa Horiguchi ◽  
Kiyohide Fushimi ◽  
...  
Keyword(s):  
Septic Shock ◽  
Renal Replacement Therapy ◽  
Continuous Renal Replacement Therapy ◽  
Replacement Therapy ◽  
Survival Benefit ◽  
Propensity Scores ◽  
Polymyxin B ◽  
Control Group ◽  
Diagnosis Procedure Combination ◽  
Polymyxin B Hemoperfusion

Background/Aims: We assessed the survival benefit of polymyxin B hemoperfusion (PMX) in septic shock patients starting continuous renal replacement therapy (CRRT), who are known to have an increased rate of mortality. Methods: Adult patients in the Japanese diagnosis procedure combination database satisfying the following criteria were enrolled: hospitalized in 2007-2012; diagnosed as having sepsis; required noradrenaline and/or dopamine; and started CRRT in intensive care unit. Propensity scores for receiving PMX were created from patient and hospital characteristics. Results: Of 3,759 eligible patients, 1,068 received PMX. Propensity-score matching produced a matched cohort of 978 pairs. The 28-day mortality was 40.2% (393/978) in the PMX group and 46.8% (458/978) in the control group (p = 0.003). Logistic regression analysis revealed a significant association between the use of PMX and decreased 28-day mortality (adjusted OR 0.75; 95% CI 0.62-0.91). Conclusion: This large retrospective study suggests that septic shock patients starting CRRT may benefit from PMX.

Sign in / Sign up

Export Citation Format

Share Document